New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
05:55 EDTAON, AON, PRGO, PRGO, NWL, NWL, NOV, NOV, MRK, MRK, MAT, MAT, LYB, LYB, LM, LM, IR, IR, BEN, BEN, XOM, XOM, CVX, CVX, BEAM, BEAM, TSN, TSNCompanies reporting Before the Market Open on FridayFebruary 1
Notable companies reporting before the opening bell on Friday include Aon (AON), Beam (BEAM), Chevron (CVX), Exxon Mobil (XOM), Franklin Resources (BEN), Ingersoll-Rand (IR), Legg Mason (LM), LyondellBasell Industries (LYB), Mattel (MAT), Merck (MRK), National Oilwell Varco (NOV), Newell Rubbermaid (NWL), Perrigo (PRGO), and Tyson Foods (TSN).
News For AON;BEAM;CVX;XOM;BEN;IR;LM;LYB;MAT;MRK;NOV;NWL;PRGO;TSN From The Last 14 Days
Check below for free stories on AON;BEAM;CVX;XOM;BEN;IR;LM;LYB;MAT;MRK;NOV;NWL;PRGO;TSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 15, 2014
17:14 EDTBEAMPershing Square lowers stake in Beam to 5.5% from 7.1%
Subscribe for More Information
10:29 EDTBEAMOptions with increasing implied volatility: YOKU CWH BEAM
Subscribe for More Information
08:23 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:10 EDTMATMattel April volatility elevated at 60 into Q1 and outlook
Subscribe for More Information
06:32 EDTMRKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
17:01 EDTAONAon plc raises annual dividend 43%
Aon plc announced that its Board of Directors has authorized a 43% increase to its annual cash dividend paid quarterly on Aon's outstanding Class A Ordinary Shares. Consistent with the increase in the dividend, the Board of Directors has declared a quarterly cash dividend of 25c per share on outstanding Class A Ordinary Shares, reflecting a 43% increase from 17.5c per share. The dividend is payable May 15 to shareholders of record on May 1.
15:44 EDTTSNTyson, Post final contenders to buy Michael Foods, Reuters says
Michael Foods, the egg and dairy products maker that has been put up for sale by Goldman Sachs' (GS) private equity arm, is evaluating binding bids from Tyson (TSN) and Post (POST) and is near a deal to be sold to one of the two for close to $2.5B, according to Reuters, citing people familiar with the matter. Reference Link
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
13:43 EDTBENFidelity to pitch new lost cost trading venue to large asset managers, WSJ says
Fidelity is working on a new trading venue, dubbed "Sakura," that it hopes will be a collaboration among big mutual-fund firms to reduce costs and streamline trading and will be an improvement over other "dark pools," reported The Wall Street Journal, citing people with knowledge of the matter. The report said Fidelity is in the initial planning stages and has just started pitching the idea to other large asset managers. Publicly traded fund managers include BlackRock (BLK), Franklin Resources (BEN) and T. Rowe Price (TROW), while Investment Technology Group (ITG) currently operates dark pools that facilitate block trading among large institutions. Exchange operators Nasdaq (NDAQ) and Intercontinentalexchange's (ICE) NYSE have previously testified to legislators that too much trading occurs in dark pools, hurting investors. Reference Link
12:46 EDTCVXChevron management to meet with Jefferies
Meetings to be held in London on April 16-17 hosted by Jefferies.
09:37 EDTCVX, MRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTCVXChevron, YPF continue development of Vaca Muerta Shale in Argentina
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:58 EDTLMLegg Mason reports Assets Under Management $702B as of March 31
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use